We operate a diversified business model across three core businesses:
The first and largest is our Branded business, which focuses on
the MENA region. In this business we manufacture and sell Branded
generic pharmaceuticals – for example, we sell a generic version of
GSK’s Augmentin under our own Hikma brand name – AMOCLAN. We also
have 33 branded products, many of which are still under patent,
that we sell under-license from the originator.
» Find out more about our Branded
business
Our Generics business operates in the competitive US market. We
develop, manufacture and market non-branded generic pharmaceutical
products. As this market is extremely competitive, we operate as a
niche player, selling a broad mix of both high and low volume
products.
» Find out more about our Generic
business
Our second largest business is the Injectables business. We
develop, manufacture and market generic injectable pharmaceuticals
as well as some branded injectable products under-licence. This
business is geographically diverse with sales into US, MENA and
Europe.
» Find out more about our Injectable
business